AnaptysBio Q1 net loss $39.3M ($1.28/sh); rosnilimab Phase 2b RA data positive; $75M buyback authorized

ANAPTYSBIO, INC

2025-Q1 EPS reported -$1.28 revenue$27,771,000

Cash and investments $383M as of March 31, 2025, with cash runway through year-end 2027.
Collaboration revenue $27.8M (up from $7.2M YoY), driven by Jemperli royalties and Vanda license.
R&D expenses $41.2M, up from $37.0M YoY, primarily due to rosnilimab RA/UC and preclinical programs.
Rosnilimab achieved highest-ever CDAI LDA response in 424-patient Phase 2b RA trial; six-month data surpassed competitors.
Initial Phase 2 UC data for rosnilimab expected Q4 2025; GSK Jemperli $1B sales milestone still anticipated 2025/2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.